Assessment of bone mineral density in men with de novo metastatic castration-sensitive prostate cancer treated with or without abiraterone acetate plus prednisone in the PEACE-1 phase 3 trial
European Journal of Cancer · 2025-03 · 218 · 115293
DOI: 10.1016/j.ejca.2025.115293 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Cancer, 2025-03. Verfasst von Guilhem Roubaud und 19 weiteren Autor:innen. Beteiligte Einrichtung: Institut Bergonié, Bordeaux, France. Electronic address: g.roubaud@bordeaux.unicancer.fr. Hauptthemen laut MEDLINE: Abiraterone Acetate, Antineoplastic Combined Chemotherapy Protocols, Bone Density, Prednisone. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: Ipsen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institut Bergonié, Bordeaux, France. Electronic address: g.roubaud@bordeaux.unicancer.fr.
- University Hospital Bordeaux, France.
- St. Vincent's University Hospital, Dublin, Ireland.
- Institut Gustave Roussy, University of Paris-Saclay, Villejuif, France.
- Vall d'Hebron Hospital, Barcelona, Spain.
- Centre Francois Baclesse, Caen, France.
Förderung
- Ipsen
Zitieren
APA
Roubaud, G., Kostine, M., McDermott, R. S., Bernard-Tessier, A., Maldonado, X., Silva, M., Fléchon, A., Berthold, D. R., Ronchin, P., Tombal, B. F., Mourey, L., Gravis, G., Escande, A., Abadie-Lacourtoisie, S., Maurina, T., Climent, M. A., Ribault, H., Bossi, A., Foulon, S., & Fizazi, K. (2025). Assessment of bone mineral density in men with de novo metastatic castration-sensitive prostate cancer treated with or without abiraterone acetate plus prednisone in the PEACE-1 phase 3 trial. European Journal of Cancer, 218, 115293. https://doi.org/10.1016/j.ejca.2025.115293
Vancouver
Roubaud G, Kostine M, McDermott RS, Bernard-Tessier A, Maldonado X, Silva M, et al. Assessment of bone mineral density in men with de novo metastatic castration-sensitive prostate cancer treated with or without abiraterone acetate plus prednisone in the PEACE-1 phase 3 trial. European Journal of Cancer. 2025;218:115293. doi:10.1016/j.ejca.2025.115293
BibTeX
@article{Roubaud2025,
author = {Roubaud, Guilhem and Kostine, Marie and McDermott, Raymond S and Bernard-Tessier, Alice and Maldonado, Xavier and Silva, Marlon and Fléchon, Aude and Berthold, Dominik R and Ronchin, Philippe and Tombal, Bertrand F and Mourey, Loïc and Gravis, Gwenaëlle and Escande, Anne and Abadie-Lacourtoisie, Sophie and Maurina, Tristan and Climent, Miguel A and Ribault, Hélène and Bossi, Alberto and Foulon, Stéphanie and Fizazi, Karim},
title = {Assessment of bone mineral density in men with de novo metastatic castration-sensitive prostate cancer treated with or without abiraterone acetate plus prednisone in the PEACE-1 phase 3 trial},
journal = {European Journal of Cancer},
year = {2025},
volume = {218},
pages = {115293},
doi = {10.1016/j.ejca.2025.115293}
}
EUVIMED